It is made available under a CC-BY-NC-ND 4.0 International license .

Neurohistopathological Findings of the Brain Parenchyma After Long-Term Deep Brain Stimulation: Case Series and Systematic Literature Review

3 AUTHORS

- 4 Juan Vivanco-Suarez^{1*}, MD; Timothy Woodiwiss^{1*}, MD; Kimberly L. Fiock², PhD; Marco M. Hefti²,
- 5 MD; Nandakumar S. Narayanan³, MD, PhD; Jeremy D. W. Greenlee¹, MD
- ^{*}Both authors contributed equally.
- 7

8 AFFILIATIONS

- ⁹ ¹ Department of Neurosurgery, University of Iowa, Iowa City, IA, United States
- ² Department of Pathology, University of Iowa, Iowa City, IA, United States.
- ³ Department of Neurology, University of Iowa, Iowa City, IA, United States.
- 12

13 CORRESPONDENCE

- 14 Jeremy D. W. Greenlee, MD,
- 15 Department of Neurosurgery, University of Iowa Hospitals and Clinics,
- 16 200 Hawkins Dr, 1826 JPP, Iowa City, IA 52242, United States.
- 17 E-mail address: jeremy-greenlee@uiowa.edu, phone: (319) 356-2771
- 18

19 SHORT RUNNING TITLE

- 20 Neurohistopathological findings after deep brain stimulation
- 21

22 KEYWORDS

- 23 Parkinson's disease; Neuropathology; Gliosis; Postmortem
- 24

25 ELEMENTS COUNTS

- 26 Abstract: 302 words
- 27 Text: 3529 words
- 28 References: 48
- 29 Tables: 2
- 30 Figures: 1
- 31 Supplemental tables: 5
- 32 Supplemental figures: 0
- 33

34 PREVIOUS PRESENTATION

35 None

3637 ETHICS

- 38 None
- 39

40 CONFLICTS OF INTEREST

- 41 The authors report no disclosures.
- 42
- 43 FUNDING
- 44 This research received no specific grant from any funding agency in public, commercial, or not-for-profit
- 45 sectors.

It is made available under a CC-BY-NC-ND 4.0 International license .

46 Neurohistopathological Findings of the Brain Parenchyma After Long-Term Deep Brain

47

Stimulation: Case Series and Systematic Literature Review

48 ABSTRACT

- 49 *Introduction:* The efficacy of deep brain stimulation (DBS) has been established to treat several
- 50 movement and psychiatric disorders. However, several aspects, such as the mechanism of action and
- 51 tissue changes after treatment are incompletely described. Hence, we aimed to describe the
- neurohistopathological findings of 9 patients who underwent DBS for movement disorders. Additionally,
- 53 we performed a systematic literature review on postmortem studies after DBS implantation.
- 54 *Methods:* We performed a retrospective study of patients who underwent DBS for movement disorders
- between 2000-2023 and had postmortem autopsy. Demographics, clinical features, and outcomes were
- 56 collected. Levodopa equivalent daily dose (LEDD) and total electrical energy delivered (TEED) were
- 57 calculated. Neurohistopathological assessments were performed from autopsies. A systematic literature
- 58 review was conducted to summarize the literature.
- 59 *Results:* Postmortem neurohistopathologic assessment of 9 patients who underwent DBS for movement
- 60 disorders (8 Parkinson's disease [multiple system atrophy was final diagnosis in 1], and 1 parkinsonism)
- 61 was performed. Median age at DBS implantation was 65 years (range, 54-69), and most were male (8
- 62 patients, 89%). Most common DBS target was the subthalamic nucleus (8 patients, 89%). Median DBS
- duration was 65 months (range, 7-264 months). Post-DBS reduction in LEDD was found in 7/9 patients,
- 64 and TEED was increased over time in 5/7 patients. No patients died due to DBS. Neurohistopathological
- assessment showed gliosis in 7 (78%) patients and activated microglial infiltration in 1 (11%).
- Additionally, postmortem findings (after DBS) of 59 patients (between 1977-2021) were identified in the
- 67 literature: 26 (44%) for Parkinson's disease, 20 (34%) for pain, and 13 (22%) for other conditions.
- 68 *Conclusion:* Our findings confirm the presence of a local tissue reaction, including gliosis and activated
- 69 microglial infiltration around the implanted DBS electrodes. The effect of the local changes on the
- 70 clinical efficacy of DBS is not established. Further DBS postmortem studies and standardization of tissue
- 71 processing are needed.
- 72

73 ABBREVIATIONS

- 74 DBS, deep brain stimulation; LEDD, Levodopa equivalent daily dose; MSA, multiple system atrophy;
- 75 PD, Parkinson's disease; TEED, total electrical energy delivered.
- 76

It is made available under a CC-BY-NC-ND 4.0 International license .

77 INTRODUCTION

78 The efficacy of deep brain stimulation (DBS) has been established for the treatment of several movement and psychiatric disorders.¹ Furthermore, its experimental application for chronic pain, obesity, 79 80 and other neurocognitive disorders has continually expanded, aiming to benefit a broader group of 81 patients.² However, several aspects of this treatment are not completely defined, including the specific 82 interaction and activation of surrounding structures, the local tissue changes in the brain caused by long-83 term stimulation, the potential adverse tissue responses induced by the electrode, and the existence of neuronal damage.^{1,3} A deeper understanding of the chronic local glial responses after electrode 84 85 implantation may provide helpful insights for the improvement of anatomical targets and the optimization 86 of electrode design according to the target tissue.

87 Previously published postmortem studies have begun the characterization of histological changes 88 occurring around electrodes in response to implantation and chronic stimulation. A comprehensive review performed by DiLorenzo et al. reported 40 cases with implanted systems from as early as 1977.⁴ The 89 90 authors showed that in more than 50% of the cases, there was local fibrosis, astrocytosis, multinucleated giant cells, mononuclear leukocytes, macrophages, activated microglia, and neuronal loss.^{4,5} Of note, 91 persistent efficacy was more commonly observed when tissue injury was absent. More recently, Vedam-92 93 Mai et al. found that 3 out of 4 DBS cases exhibited histopathological evidence of a glial collar or scar 94 around the electrode, but there was no significant association between DBS duration and the amount of gliosis. As the technologies and techniques employed for DBS continue to evolve, the evidence regarding 95 the local changes around the electrode is contradictory.⁶⁻⁹ For instance, data on the comparison of 96 97 histological samples from patients with active and inactive electrodes is limited, the effect of the size of 98 the gliotic scar is uncertain, and evidence of the distance (from the electrode) where neuronal loss or preservation is observed is unclear.¹⁰ 99

Hence, this study aims to characterize and describe the neurohistopathological environment of the
 brain parenchyma surrounding DBS electrodes in 9 patients who underwent surgical treatment for
 Parkinson's disease (PD) or a parkinsonism syndrome. Additionally, we present an updated and expanded
 summary of the literature on this topic with a systematic review of postmortem studies after DBS
 implantation.

105

106 METHODS

107 Study design, patient protocol, tissue acquisition, and storage

108 This was a retrospective study of adult patients who underwent DBS for movement disorders at a 109 tertiary academic center between July 2000 and April 2023. All tissue was obtained from autopsies

110 conducted at the University of Iowa Hospitals and Clinics as part of routine clinical care in accordance

It is made available under a CC-BY-NC-ND 4.0 International license .

with all applicable federal and state laws and regulations. Consent for the use of tissue in research was 111 obtained from the next of kin as part of the autopsy consent. This project was reviewed by the University 112 113 of Iowa Institutional Review Board and determined not to represent human subjects research under the 114 National Institutes of Health Revised Common Rule. Based on the database created for each donor, for 115 this study, we extracted the age at diagnosis, sex, duration of disease, calculated Levodopa equivalent daily dose (LEDD)¹¹ (before implantation, 6 ± 3 months after DBS, and at last clinical follow-up), age 116 at DBS implantation, intraoperative and hospitalization complications, DBS duration, post-implantation 117 stimulation parameters (at 6 $[\pm 3]$ months after DBS, at last clinical follow-up), and age at death. To 118 assess the stimulation parameters, we calculated total electrical energy delivered (TEED)¹² (impedance 119

120 121

122 Neurohistopathological techniques and evaluation

was set to 1000Ω to standardize calculations).

Tissue processing was done as previously described.¹³⁻¹⁵ Briefly, brains were fixed in 20% neutral buffered formalin for 10-14 days and then sectioned, sampled, processed, and stained (both histochemical and immunohistochemical stains) in the Emory Warner Clinical Pathology Laboratories of the University of Iowa according to standard protocols. A board-certified neuropathologist (MMH) and PhD-trained research neuropathologist (KLF) reviewed all tissue sections and stains.

128

129 Systematic literature review and data extraction

130 A comprehensive literature search of the MEDLINE (via PubMed) database using medical subject 131 heading terms, entrees, and free text to identify all published postmortem neurohistopathological reports 132 of DBS cases (end-of-search date: August 9, 2023). The complete search strategy is found in Supplemental Table 1. All DBS cases, regardless of indication or anatomical target in the human brain, 133 134 were included. Review articles or meta-analyses that did not describe disaggregated data on DBS cases 135 were excluded. Two independent reviewers (TW and JV-S) screened the articles using the Rayyan tool 136 (https://www.rayyan.ai/). Any difference between reviewers was settled through discussion. After the 137 initial selection of eligible studies, the reference lists were thoroughly searched to identify additional eligible studies based on the "snowball" methodology.¹⁶ Because DiLorenzo et al. thoroughly reviewed 138 139 the literature in 2014, we expanded our review to new cases either missed by the aforementioned authors 140 or reported after the review was completed. The following data were collected using a standardized data 141 extraction form: demographic and patient characteristics, information about implanted hardware, 142 stimulation parameters, clinical course, and neuropathological findings. Clinical efficacy and decline after 143 DBS were extracted as defined by the authors of each study. When critical or disaggregated information 144 was missing, the studies were excluded.

It is made available under a CC-BY-NC-ND 4.0 International license .

145

146 **RESULTS**

147 Patient demographics, clinical, and DBS characteristics

148 A total of 9 patients who had DBS implantation were identified from our institutional autopsy 149 database. The patient and neurohistopathologic characteristics are described in Table 1. The median age 150 of disease onset was 52 (range, 47-64 years), and 8 (89%) were male. On preoperative clinical evaluation, 151 PD was diagnosed in 8 (89%) patients and parkinsonism in 1 (11%). Of note, patient 9 presented 152 clinically as PD with a very robust response to levodopa for several years. However, dysautonomic 153 symptoms and ataxia emerged throughout the disease course, pointing to the diagnosis of a slowly 154 evolving Parkinsonian variant multiple system atrophy (MSA), which was confirmed on postmortem 155 neurohistopathologic evaluation. 156 Regarding the DBS characteristics, the median disease course before DBS implantation was 7 years 157 (range, 3-20 years). The median patient age at DBS implantation was 65 years (range, 54-69 years). All 158 patients received bilateral DBS lead implantation; the majority received electrodes targeting the bilateral 159 subthalamic nuclei (8, 89%). One (11%) patient received leads targeting the globus pallidus interna. 160 Patient 3 had an additional lead implanted in the left ventralis intermedius thalamic nucleus due to 161 refractory right-sided tremor. All electrodes were made of platinum/iridium (Medtronic, Inc.). The 162 median DBS duration was 65 months (range, 7-262 months). Patient 5 underwent unilateral DBS removal 163 (extension and battery) 16 years after bilateral implantation due to a neck infection surrounding the left-164 sided extension wire. No intracranial infection was identified. He was successfully reimplanted 3 months 165 later after adequate infection management with replacement of the left STN lead and extension and battery replacement. Patient 8 had a right lead incision/burr hole erosion and infection necessitating 166 167 complete bilateral DBS hardware removal 13 months after implantation. No intracranial infection was 168 identified At last follow-up, the TEED increased in 5 of 7 patients with available data by a mean of 151 169 J-s compared to their initial DBS settings. However, in patients 8 and 9, the TEED decreased slightly (1 and 21 J·s, respectively) from their initial parameters. A mean LEDD reduction of 28% was observed in 7 170 171 patients after DBS began. On the other hand, LEDD increased in patients 4 and 6 by 67% and >100%, 172 respectively. Additional details about the LEDD and TEED are presented in Supplemental Table 2. In

terms of mortality, 1 patient (11%, case 9) passed away due to disease progression, 4 (44%) died due to

unknown causes, and the remaining 4 (44%) passed away due to reasons unrelated to the primary diseaseor an unknown cause.

176

177 Postmortem neurohistopathological characteristics

It is made available under a CC-BY-NC-ND 4.0 International license .

178 An example of the gross and microscopic findings is presented in Figure 1 (A-E). Table 1 shows a 179 descriptive summary of the postmortem neurohistopathologic findings. All patients except 2 showed 180 gliosis at the DBS lead site. One of the 2 only had DBS for 7 months due to a fatal fall, while the other 181 showed no gliosis despite DBS for 140 months. Activated microglial infiltration was seen around the lead 182 in 1 patient. For the 7 patients who developed gliosis around the DBS lead, the median DBS duration was 183 65 months (range, 13-262). TEED increased over time in 4 patients (mean of 178 J-s) and decreased in 2 184 (1 and 21 J·s, respectively). A mean LEDD reduction of 32% was observed in 5/7 patients after DBS 185 compared to pre-operative values. Two patients required an increase of their LEDD over time of 67% and 186 >100%, including the lone PD patient treated with globus pallidus interna DBS. Notable 187 neurohistopathologic changes from the tissue sections are the following: substantia nigra depigmentation 188 was found in 2 (22%) patients (cases: 1 and 3) and nigra cell loss in 7 (78%; cases: 1, 4, 5, 6, 7, 8, and 9). 189 Patient 1 had a combination of nigra depigmentation and nigra cell loss. There were a variety of 190 additional neurodegenerative pathologic findings, including the presence of Lewy bodies in 5 patients (56%; cases: 2, 3, 4, 5, and 6) at different anatomical structures, neurofibrillary tangles in 4 (44%; cases: 191 192 5, 6, 8, and 9), tau aggregates in 4 (44%; cases: 2, 5, 8, and 9), beta-amyloid plaques in 3 (33%; cases: 5, 193 6, and 8), TDP-43 inclusions in 2 (22%; cases: 2 and 5), and inclusions of alpha-synuclein in 1 (11%, case 194 9). Of note, all but one assessed patients with 12 years or longer of PD duration at the time of death 195 showed Lewy bodies. Finally, other pathological findings (distant to the tract) including hemorrhages and 196 subacute infarcts were reported in 3 (33%) patients (cases 6, 7, and 8).

197

198 Systematic review update: study selection and characteristics

199The literature review yielded 1249 articles, from which 18 duplicates were removed. As a result of

200 the initial screening by title and abstract, there were 48 potentially eligible articles. In the full-text

evaluation, 16 documents were excluded for the following reasons: ineligible study type (n=6),

insufficient data available (n=5), ineligible outcomes (n=3), and ineligible patient population (n=2).

203 Ultimately, 32 studies (25 case reports and 7 case series) from the final systematic search were included.

From the studies, a total of 59 patients who had a postmortem neurohistopathological assessment

after DBS implantation (for different conditions) were identified. The studies were performed between

1977 and 2021. Fifteen were conducted in Europe $^{6,7,10,17-28}$, 13 in North America $^{29-41}$, 3 in Australia $^{42-44}$,

- and 1 in Asia⁴⁵. The number of patients per study ranged from 1 to 8. In terms of the conditions for which
- 208 DBS was implanted, 26 (44%) patients were treated for PD between 1994 and 2021 (Table 2; 2 MSA
- 209 cases were initially misdiagnosed as PD), 6 (10%) for epilepsy (4 cases had cerebellar stimulation)
- between 1979 and 2020 (Supplemental material Table 3), 20 (34%) for pain between 1977 and 1991

It is made available under a CC-BY-NC-ND 4.0 International license .

- (Supplemental material Table 4), and 7 (12%) for other conditions (tremor, chorea-acanthocytosis, and
 diffuse Lewy body disease) between 2000 and 2011 (Supplemental material Table 5).
- 213

214 Literature PD patients: DBS characteristics

Regarding the 26 PD patients (cases 11^{18} and 15^{30} were confirmed to be MSA on autopsy), the age at 215 DBS implantation ranged from 24 to 81 years, and most were males (21; 81%). The DBS targets were the 216 217 subthalamic nucleus in 16 (62%) patients (15 bilateral and 1 left side), the ventralis intermedius thalamic 218 nucleus in 8 (31%; 3 bilateral, 3 right, 2 left, and 1 unknown), the left centromedian-parafasicular 219 complex thalamic region in 1 (4%), and the bilateral zona incerta in 1 (4%). Platinum/iridium electrodes 220 were the most employed. DBS duration ranged from 2 days to 144 months. Three cases passed away within 1 month after DBS implantation. Case 9 passed away 2 days after implantation due to myocardial 221 infarction.¹⁰ Case 11 was readmitted 19 days after lead placement surgery due to abnormal behavior, 222 impaired gait, fever, and lethargy. DBS was discontinued, and medical management was started.¹⁸ 223 224 However, after transient improvement, the patient died 2 days later due to a massive pulmonary embolism 225 (identified in autopsy). Case 13 died 4 days after implantation due to cardiorespiratory arrest secondary to 226 pulmonary embolus (identified in autopsy). Clinical efficacy (as reported by the authors of each study) 227 was observed in 24 patients (92%), and decline was reported in 4 (15%). Death causes were diverse. 228 However, none of them were encountered intraoperatively during DBS implantation.

229

230 Literature PD patients: postmortem neurohistopathological characteristics

231 In terms of the postmortem neurohistopathological analysis, fibrillary gliosis (which represents a 232 chronic tissue reaction) was reported in 23/24 (92%) patients, and in 2/26 (8%) patients, it could not be 233 assessed due to precipitated death (details discussed above). In the patients who passed away within 1 234 month after implantation, fresh hemorrhage was evidenced in 2/3 (67%). Reactive astrocytosis (mostly 235 reflective of an acute tissue reaction) was observed in 14/25 (56%) patients. Microglial activation was found in 9/17 (53%) patients, and neuronal loss was observed in 7/19 (37%) patients. Multinucleated 236 237 giant cells were reported in 8/25 (32%) patients. Regarding the pathologic findings of PD, nigra 238 depigmentation was reported in 24/24 (100%) patients, and nigra cell loss in 21 (81%). Of note, in the 239 cases where MSA was confirmed on autopsy (2/26, 8%), DBS showed clinical efficacy only in case 11.

240

241 DISCUSSION

In this study of the neurohistopathological findings of 9 patients implanted with platinum/iridium DBS electrodes for parkinsonism (1 patient), PD (7 patients), and parkinsonian type MSA (1 patient), we found that at a median time of 65 months after DBS implantation, the brain tissue surrounding the DBS

It is made available under a CC-BY-NC-ND 4.0 International license .

245 resulted in gliosis in 7 patients (78%) and the presence of activated microglia in 1 patient (11%). In 246 general, these results are consistent with previous postmortem studies showing that a glial response is consistently generated around the DBS electrodes. Additionally, our systematic review spanning between 247 248 1977 and 2021 of postmortem neuropathological studies reporting findings after DBS identified 59 249 unique patients who underwent treatment for PD, epilepsy, pain, and other conditions such as tremor, 250 chorea-acanthocytosis, and diffuse Lewy body disease. As the number of patients treated with DBS (for a 251 wide variety of conditions) increases and the technologies continue to evolve, our study represents an 252 addition to the body of evidence on the postmortem findings after DBS and represents the most 253 comprehensive and current review of this topic.

254

255 Gliosis surrounding the implantation site

256 The presence of a gliotic response surrounding the DBS electrode described in this study is similar to the findings reported in previous postmortem human studies and animal models.² Yet, our rate of 78% 257 258 (7/9 patients) gliotic response after a range of 7-262 months following DBS implantation is lower than the 259 overall rate of gliotic responses reported in the literature (92%, 22/24 patients). Notably, one of our patients without gliosis had DBS for 7 months. Previous studies have attributed the reaction of the brain 260 parenchyma to the electrode itself and/or the chronic stimulation.³² More study is needed to understand if 261 262 these factors, such as the biocompatibility of the implanted electrodes, the variability in the stimulation 263 parameters, degradation of the metal contacts, and the length of stimulation (and others), could be 264 implicated in the process of gliotic scar formation. The clinical implication (effect upon efficacy 265 variation) of the gliotic response around the DBS electrode is poorly described. The plausibility that an 266 increased gliotic response negatively affects DBS efficacy seems reasonable and intuitive. However, in 267 our study, from the 7 patients who developed gliotic changes, 5 had a 32% reduction in their LEDD at the 268 last follow-up compared to pre-DBS dosage. This contrasted with the 2 patients who needed a greater 269 than 50% LEDD increase over their post-implantation course. Of note, these patients (4 and 6 from Table 270 1) had the lowest pre-DBS LEDD levels and a prolonged DBS treatment (65 and 94 months, 271 respectively). Also, patient 6 was the only one who received stimulation of the globus pallidus interna, 272 which is known to not reduce LEDD after DBS compared to patients treated with STN DBS. Given the 273 variability in our findings, the limited sample size, and the lack of standardization in the assessment of 274 gliosis around the DBS electrode, additional studies will be needed with objective clinical findings, such 275 as LEDD and TEED, compared to in depth histological evaluation, such as volume and density of gliosis, 276 before robust conclusions can be made. Separating the gliosis produced by the implantation lesion and the 277 simulation-induced effects is also relevant for optimizing clinical efficacy. Thus, we recommend that 278 future studies evaluate the potential correlation between the gliotic scar and the clinical efficacy of DBS

It is made available under a CC-BY-NC-ND 4.0 International license .

- treatment to provide needed insights for developing biocompatible materials, optimizing stimulation
- 280 parameters, and implantation techniques that optimize patient outcomes.
- 281

282 Additional neurohistopathologic findings

283 Evidence of additional markers of local tissue response (to the implanted electrodes), such as 284 activated microglia, reactive astrocytosis, giant multinuclear cells, hemosiderin-laden macrophages, and neuronal loss, have been reported in previous studies.^{2,4,8} In our series, only one (11%) case (patient 2) 285 demonstrated activated microglia infiltration, which was lower than the 53% we found in the literature 286 287 review. The presence of activated microglia lacks specificity but supports the presence of an ongoing 288 inflammatory response regardless of the chronicity of the electrode implantation. Furthermore, in the 289 literature review, we found additional tissue responses such as astrogliosis (53%), multinucleated giant 290 cells (32%), and neuronal loss (37%). Although these findings are unspecific and were not assessed in our series, their description, characterization, and role in the therapeutic action of DBS are of great interest. 291 292 Support for more postmortem neurohistopathologic after DBS is also supported by our findings of change 293 in diagnosis over time in our series and the literature. In our study 1 patient was confirmed to have MSA after DBS implantation for PD, while in the literature, 2 cases^{18,30} had a similar update to MSA after 294 295 postmortem assessment. The lack of consistent efficacy in these cases confirms the need for an accurate 296 diagnosis to obtain the best clinical results. Clinical research would benefit from pathologically confirmed 297 diagnosis to ensure data is accurate. Additional knowledge about DBS and its mechanisms could allow 298 for the inclusion of other indications in which the therapy could have potential benefits.

299

300 Future directions

301 Although the neurohistopathological changes observed in the tissue surrounding the DBS electrodes 302 show characteristics of a classical foreign body reaction, the presence of additional changes (around the 303 active electrodes) and their underlying mechanisms are yet to be elucidated. The response of different 304 cellular lines (neurons, glial cells, immune cells, and vasculature-related cells) to electrical stimulation is 305 not established.¹ Determination of the influence of electrical currents (at varying intensities and charge 306 densities) on neuronal signaling, neural function, astrocyte response, and overall cellular metabolism 307 could provide valuable insights to tailor and optimize the stimulation parameters to favor minimal injury, 308 maximal long-lasting efficacy, and expansion of the contemporary indications for DBS. Additionally, the 309 development and testing of electrodes (and coatings) with novel functional biomaterials aiming to 310 minimize the immune response, decrease tissue resistance to stimulation (impedance), favor the attraction 311 of the neuronal processes (potentially enhancing the benefits of DBS), and optimize the charge transfer 312 density. Such efforts are underway employing nanomaterials and nanoparticles that minimize the tissue

It is made available under a CC-BY-NC-ND 4.0 International license .

reaction, favor neural recordings, and improve charge transfer efficiency.⁴⁶ Despite this, the use of 313 314 postmortem neurohistopathological data continues to provide valuable and fundamental insights to guide 315 future directions. However, the postmortem literature is largely dominated by studies with low-level 316 evidence (case reports and case series), lacking standard tissue handling and assessment protocols. The 317 formation of an integrated network of researchers, the adoption of common protocols for the collection 318 and management of specimens, and the implementation of new techniques for tissue evaluation seem to 319 be the natural next step in the evolution of the study of human neurodegenerative and neuropsychiatric disease and the role of DBS with them.^{47,48} 320

321

322 Limitations

323 We acknowledge that our study has limitations. First, the sample size was small, and the analysis 324 was retrospective. Next, the clinical outcome data were limited by availability and patient follow-up Additionally, the handling, processing, and evaluation of the neurohistopathological samples were 325 326 performed according to local protocols, which limits the comparison and generalizability of our findings. 327 Regarding the systematic review, the included studies were small (case reports and series) and 328 retrospective. The clinical data and postmortem neurohistopathological findings were heterogeneously 329 reported based on the individual selection and preference of the authors from each study. However, 330 considering the limited availability of such data and the lack of standardization on the protocols for 331 neurohistopathological tissue handling, we included all the available reports aiming to comprehensively 332 summarize the existing literature.

333

334 CONCLUSION

335 Our findings confirm the presence of a local tissue reaction, including gliosis and activated 336 microglial infiltration around the implanted DBS electrodes. The presence of additional histologic 337 changes has been reported in the literature however, the implication of these findings needs to be clearly 338 established. The effect of the local changes on the clinical efficacy of DBS is not clearly established. As 339 the continual effort to expand the use, efficacy, and safety of DBS for neuromodulation and 340 neuroaugmentation moves forward, the value of postmortem neurohistopathological evidence will 341 undoubtedly shed more light on the mechanism behind this powerful clinical and surgical tool. Further DBS postmortem studies and standardization of tissue processing are needed to expand the understanding 342 343 of the interaction between the local brain parenchyma and the implanted DBS electrode. 344

345 ACKNOWLEDGMENTS

- 346 The authors would like to acknowledge the incredible contribution of the patient donors and their
- 347 families, as this research would not be possible without their generous gift to the advancement of science.
- 348 They would also like to acknowledge the support staff at the University of Iowa who worked tirelessly
- behind the scenes to keep our facilities running. If there are additional comments/suggestions, please let
- 350 us know.
- 351

It is made available under a CC-BY-NC-ND 4.0 International license .

352 **REFERENCES**

- 1. Evers J, Lowery M. The Active Electrode in the Living Brain: The Response of the Brain
- 354 Parenchyma to Chronically Implanted Deep Brain Stimulation Electrodes. *Oper Neurosurg*

355 (*Hagerstown*). Jan 13 2021;20(2):131-140. doi:10.1093/ons/opaa326

- 2. Orlowski D, Michalis A, Glud AN, et al. Brain Tissue Reaction to Deep Brain Stimulation-A
- Longitudinal Study of DBS in the Goettingen Minipig. *Neuromodulation*. Jul 2017;20(5):417-423.
- doi:10.1111/ner.12576
- 359 3. Fenoy AJ, Goetz L, Chabardès S, Xia Y. Deep brain stimulation: are astrocytes a key driver
- behind the scene? *CNS Neurosci Ther*. Mar 2014;20(3):191-201. doi:10.1111/cns.12223
- 4. DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Neurohistopathological findings at
- the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case

report, and assessment of stimulation threshold safety. *Neuromodulation*. Jul 2014;17(5):405-18;

discussion 418. doi:10.1111/ner.12192

365 5. Moss J, Ryder T, Aziz TZ, Graeber MB, Bain PG. Electron microscopy of tissue adherent to

- explanted electrodes in dystonia and Parkinson's disease. *Brain*. Dec 2004;127(Pt 12):2755-63.
- 367 doi:10.1093/brain/awh292
- 368 6. Al-Helli O, Thomas DL, Massey L, et al. Deep brain stimulation of the subthalamic nucleus:
- histological verification and 9.4-T MRI correlation. *Acta Neurochir (Wien)*. Dec 2015;157(12):2143-7.

doi:10.1007/s00701-015-2599-x

7. De Vloo P, Thal D, van Kuyck K, Nuttin B. Histopathology after microelectrode recording and
twelve years of deep brain stimulation. *Brain Stimul.* Sep-Oct 2018;11(5):1183-1186.

- doi:10.1016/j.brs.2018.05.005
- Vedam-Mai V, Rodgers C, Gureck A, et al. Deep Brain Stimulation associated gliosis: A post mortem study. *Parkinsonism Relat Disord*. Sep 2018;54:51-55. doi:10.1016/j.parkreldis.2018.04.009

9. Vedam-Mai V, Martinez-Ramirez D, Hilliard JD, et al. Post-mortem Findings in Huntington's

377 Deep Brain Stimulation: A Moving Target Due to Atrophy. *Tremor Other Hyperkinet Mov (N Y)*.

- 378 2016;6:372. doi:10.7916/d8zp462h
- Haberler C, Alesch F, Mazal PR, et al. No tissue damage by chronic deep brain stimulation in
 Parkinson's disease. *Ann Neurol.* Sep 2000;48(3):372-6.
- 11. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa
- dose equivalency reporting in Parkinson's disease. *Mov Disord*. Nov 15 2010;25(15):2649-53.
- 383 doi:10.1002/mds.23429

- 12. Koss AM, Alterman RL, Tagliati M, Shils JL. Calculating total electrical energy delivered by
- deep brain stimulation systems. *Ann Neurol.* Jul 2005;58(1):168; author reply 168-9.
- 386 doi:10.1002/ana.20525
- 13. Fiock KL, Hook J, Hefti MM. Determinants of Astrocytic Pathology in Stem Cell Models of
- 388 Primary Tauopathies. *bioRxiv*. Jul 26 2023;doi:10.1101/2023.07.18.549558
- 14. Fiock KL, Smalley ME, Crary JF, Pasca AM, Hefti MM. Increased Tau Expression Correlates
- 390 with Neuronal Maturation in the Developing Human Cerebral Cortex. eNeuro. May/Jun
- 391 2020;7(3)doi:10.1523/eneuro.0058-20.2020
- 15. Conway KS, Ghafoor F, Gottschalk AC, et al. The Neuropathology of 1p36 Deletion Syndrome:
- An Autopsy Case Series. J Neuropathol Exp Neurol. Sep 27 2021;80(9):856-860.
- 394 doi:10.1093/jnen/nlab072
- 395 16. Wohlin C. Guidelines for snowballing in systematic literature studies and a replication in
- 396 software engineering. presented at: Proceedings of the 18th International Conference on Evaluation and
- 397 Assessment in Software Engineering; 2014; London, England, United Kingdom.
- 398 <u>https://doi.org/10.1145/2601248.2601268</u>
- 17. Caparros-Lefebvre D, Ruchoux MM, Blond S, Petit H, Percheron G. Long-term thalamic
- 400 stimulation in Parkinson's disease: postmortem anatomoclinical study. Neurology. Oct 1994;44(10):1856-
- 401 60. doi:10.1212/wnl.44.10.1856
- 402 18. Berciano J, Valldeoriola F, Ferrer I, et al. Presynaptic parkinsonism in multiple system atrophy
- 403 mimicking Parkinson's disease: a clinicopathological case study. *Mov Disord*. Jul 2002;17(4):812-6.
- 404 doi:10.1002/mds.10190
- 405 19. Jarraya B, Bonnet AM, Duyckaerts C, et al. Parkinson's disease, subthalamic stimulation, and
- selection of candidates: a pathological study. *Mov Disord*. Dec 2003;18(12):1517-20.
- 407 doi:10.1002/mds.10607
- 408 20. Nielsen MS, Bjarkam CR, Sørensen JC, Bojsen-Møller M, Sunde NA, Østergaard K. Chronic
- subthalamic high-frequency deep brain stimulation in Parkinson's disease--a histopathological study. *Eur*
- 410 *J Neurol*. Feb 2007;14(2):132-8. doi:10.1111/j.1468-1331.2006.01569.x
- 411 21. Guehl D, Vital A, Cuny E, et al. POSTMORTEM PROOF OF EFFECTIVENESS OF ZONA
- 412 INCERTA STIMULATION IN PARKINSON DISEASE. *Neurology*. 2008;70(16 Part 2):1489-1490.
- 413 doi:10.1212/01.wnl.0000310426.18409.11
- 414 22. Gelpi E, Haberler C, Micko A, et al. Focal Subthalamic Atrophy after Long-Term Deep Brain
- 415 Stimulation in Parkinson's Disease. *Mov Disord*. Aug 2021;36(8):1987-1989. doi:10.1002/mds.28653

- 416 23. Wright GD, Weller RO. Biopsy and post-mortem findings in a patient receiving cerebellar
- stimulation for epilepsy. *J Neurol Neurosurg Psychiatry*. Mar 1983;46(3):266-73.
- 418 doi:10.1136/jnnp.46.3.266
- 419 24. Giordano F, Caporalini C, Peraio S, et al. Post-mortem histopathology of a pediatric brain after
- 420 bilateral DBS of GPI for status dystonicus: case report and review of the literature. *Childs Nerv Syst.* Sep
- 421 2020;36(9):1845-1851. doi:10.1007/s00381-020-04761-w
- 422 25. Gybels J, Dom R, Cosyns P. Electrical stimulation of the central gray for pain relief in human:
- 423 autopsy data. Acta Neurochir Suppl (Wien). 1980;30:259-68. doi:10.1007/978-3-7091-8592-6_31
- 424 26. Boivie J, Meyerson BA. A correlative anatomical and clinical study of pain suppression by deep
- 425 brain stimulation. *Pain*. Jun 1982;13(2):113-126. doi:10.1016/0304-3959(82)90022-7
- 426 27. Burbaud P, Vital A, Rougier A, et al. Minimal tissue damage after stimulation of the motor
- thalamus in a case of chorea-acanthocytosis. *Neurology*. Dec 24 2002;59(12):1982-4.
- 428 doi:10.1212/01.wnl.0000038389.30437.1e
- 429 28. Valldeoriola F, Tolosa E, Alegret M, et al. Cognitive changes in Parkinson's disease during
- 430 subthalamic stimulation: a clinicopathologic study. J Neurol Neurosurg Psychiatry. Apr 2006;77(4):565-
- 431 6. doi:10.1136/jnnp.2005.077990
- 432 29. Counelis GJ, Simuni T, Forman MS, Jaggi JL, Trojanowski JQ, Baltuch GH. Bilateral
- 433 subthalamic nucleus deep brain stimulation for advanced PD: correlation of intraoperative MER and
- 434 postoperative MRI with neuropathological findings. *Mov Disord*. Sep 2003;18(9):1062-5.
- 435 doi:10.1002/mds.10489
- 436 30. Chou KL, Forman MS, Trojanowski JQ, Hurtig HI, Baltuch GH. Subthalamic nucleus deep brain
- 437 stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. *J Neurosurg*. Mar
 438 2004;100(3):553-6. doi:10.3171/jns.2004.100.3.0553
- 439 31. Sun DA, Yu H, Spooner J, et al. Postmortem analysis following 71 months of deep brain
- stimulation of the subthalamic nucleus for Parkinson disease. *J Neurosurg*. Aug 2008;109(2):325-9.
- 441 doi:10.3171/jns/2008/109/8/0325
- 442 32. Vedam-Mai V, Yachnis A, Ullman M, Javedan SP, Okun MS. Postmortem observation of
- collagenous lead tip region fibrosis as a rare complication of DBS. *Mov Disord*. Apr 2012;27(4):565-9.
- 444 doi:10.1002/mds.24916
- 445 33. Pilitsis JG, Chu Y, Kordower J, Bergen DC, Cochran EJ, Bakay RA. Postmortem study of deep
- brain stimulation of the anterior thalamus: case report. *Neurosurgery*. Feb 2008;62(2):E530-2; discussion
- 447 E532. doi:10.1227/01.neu.0000316024.81786.78

- 448 34. Robertson LT, Dow RS, Cooper IS, Levy LF. Morphological changes associated with chronic
- 449 cerebellar stimulation in the human. *J Neurosurg*. Oct 1979;51(4):510-20.
- 450 doi:10.3171/jns.1979.51.4.0510
- 451 35. Hosobuchi Y, Adams JE, Linchitz R. Pain relief by electrical stimulation of the central gray
- 452 matter in humans and its reversal by naloxone. *Science*. Jul 8 1977;197(4299):183-6.
- 453 doi:10.1126/science.301658
- 454 36. Baskin DS, Mehler WR, Hosobuchi Y, Richardson DE, Adams JE, Flitter MA. Autopsy analysis
- 455 of the safety, efficacy and cartography of electrical stimulation of the central gray in humans. *Brain Res.*
- 456 Apr 23 1986;371(2):231-6. doi:10.1016/0006-8993(86)90358-6
- 457 37. Boockvar JA, Telfeian A, Baltuch GH, et al. Long-term deep brain stimulation in a patient with
- 458 essential tremor: clinical response and postmortem correlation with stimulator termination sites in ventral
- 459 thalamus. Case report. J Neurosurg. Jul 2000;93(1):140-4. doi:10.3171/jns.2000.93.1.0140
- 460 38. Gross RE, Jones EG, Dostrovsky JO, Bergeron C, Lang AE, Lozano AM. Histological analysis of
- the location of effective thalamic stimulation for tremor. Case report. J Neurosurg. Mar 2004;100(3):547-
- 462 52. doi:10.3171/jns.2004.100.3.0547
- 463 39. McClelland S, 3rd, Vonsattel JP, Garcia RE, et al. Relationship of clinical efficacy to
- 464 postmortem-determined anatomic subthalamic stimulation in Parkinson syndrome. *Clin Neuropathol*.
- 465 Nov-Dec 2007;26(6):267-75. doi:10.5414/npp26267
- 466 40. DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Long-term deep brain stimulation
- 467 for essential tremor: 12-year clinicopathologic follow-up. *Mov Disord*. Jan 30 2010;25(2):232-8.
- 468 doi:10.1002/mds.22935
- 469 41. Hughes PS, Krcek JP, Hobson DE, Del Bigio MR. An unusual inflammatory response to
- 470 implanted deep brain electrodes. *Can J Neurol Sci.* Jan 2011;38(1):168-70.
- 471 42. Henderson JM, O'Sullivan DJ, Pell M, et al. Lesion of thalamic centromedian– parafascicular
- 472 complex after chronic deep brain stimulation. *Neurology*. 2001;56(11):1576-1579.
- 473 doi:10.1212/wnl.56.11.1576
- 474 43. Henderson JM, Pell M, O'Sullivan DJ, et al. Postmortem analysis of bilateral subthalamic
- 475 electrode implants in Parkinson's disease. *Mov Disord*. Jan 2002;17(1):133-7. doi:10.1002/mds.1261
- 476 44. Henderson J, Rodriguez M, O'Sullivan D, et al. Partial lesion of thalamic ventral intermediate
- 477 nucleus after chronic high-frequency stimulation. *Mov Disord*. Jun 2004;19(6):709-11.
- 478 doi:10.1002/mds.10709
- 479 45. Kuroda R, Nakatani J, Yamada Y, Yorimae A, Kitano M. Location of a DBS-electrode in lateral
- thalamus for deafferentation pain. An autopsy case report. *Acta Neurochir Suppl (Wien)*. 1991;52:140-2.
- 481 doi:10.1007/978-3-7091-9160-6_38

It is made available under a CC-BY-NC-ND 4.0 International license .

- 482 46. Angelov SD, Koenen S, Jakobi J, et al. Electrophoretic deposition of ligand-free platinum
- 483 nanoparticles on neural electrodes affects their impedance in vitro and in vivo with no negative effect on
- 484 reactive gliosis. J Nanobiotechnology. Jan 12 2016;14:3. doi:10.1186/s12951-015-0154-9
- 485 47. Vedam-Mai V. Biovalue in Human Brain Banking: Applications and Challenges for Research in
- 486 Neurodegenerative Diseases. *Methods Mol Biol.* 2022;2389:209-220. doi:10.1007/978-1-0716-1783-0_17
- 487 48. Vedam-Mai V, Krock N, Ullman M, et al. The national DBS brain tissue network pilot study:
- need for more tissue and more standardization. *Cell Tissue Bank*. Aug 2011;12(3):219-31.
- 489 doi:10.1007/s10561-010-9189-1

	print	medF
	(whi	₹Xiv I
	5	orep
	vas	rint
	<u>s</u>	doi:
	cen	http
	lifie	s://d
	5 5	oi.o
	pe	rg/1
	er re	0.11
•	vie	01/:
:	5	202
-	s the	.11
	aut	23.
-	hor/	2320
)	func	3886
al	der,	₩ ₩
us	who	nis v
;	has	ersi
	gra	on p
is	ntec	oste
	me	ă Z
	dRx	over
	iv a	nbe
	licer	27
	lse 1	202
	io di	
	spla	he o
	y th	bby
	epre	righ
	prin	t hol
	nt in	lder
	perr	for t
	oetu	his
	Ę	

pre

491 TABLES

Table 1. Demographic, clinical, and neurohistopathological (around the electrode track) characteristics of the patients who underwent DBS

49	13								implantat	ion					
DBS case n.	Age at onset/ sex	Disease	Age at DBS	DBS target	PD duration at death (years)	DBS duration in months ^a	LEDD change ^b	TEED change ^c	Cause of death	Gliosis at DBS site	Activated microglia at DBS lead	Nigra depigmentation	Nigra cell loss	Other neurodegenerative pathology	Other pathology
1	61-65/M	Parkinsonism	66-70	B STN	5	24	- 13% (- 200 mg)	+ 2,600% (+ 156 J·s)	Lung cancer	Yes	No	Yes	Yes	None	None
2	46-50/M	PD	66-70	B STN	32	140	- 10% (-100 mg)	NA	Unknown	No	No	No	No	 Tau limited to the amygdala Lewy bodies in the limbic system and cingulate gyrus Scant TDP-43 inclusions in the hippocampus 	None
3	51-55/M	PD	56-60	B STN L VIM	15	126 ^d	- 32% (- 350 mg)	+ 233% (+ 221 J·s)	Unknown	Yes	Yes	Yes	No	 Scant Lewy bodies in the cortex and cingulate Pigment incontinence in the substantia nigra and locus coeruleus 	None =
4	51-55/M	PD	61-65	B STN	18	65	+ 67% (+ 470 mg)	NA	COPD	Yes	No	No	Yes	 Scattered Lewy bodies in the neocortex and amygdala 	None B
5	46-50/M	PD	51-55	B STN	28	262 °	- 46% (- 425 mg)	+ 133% (+ 187 J·s)	Unknown	Yes	No	No	Yes	 Lewy bodies in the amygdala and cingulate gyrus Beta-amyloid plaques in the neocortex (Thal 1) Neurofibrillary tangles extending into the hippocampus (Braak III/IV) Scattered subpial astrocytic tau in the neocortex TDP-43 inclusions in the hippocampus 	de available
6	56-60/M	PD	61-65	B GPI	12	94	+ 213% (+ 1,785 mg)	+ 89% (+ 147 J·s)	Unknown	Yes	No	No	Yes	 Scattered Lewy bodies in the amygdala and cingulate gyrus Beta-amyloid plaques extending into the basal ganglia (Thal 3, CERAD 1) Neurofibrillary tangles extending into the primary visual cortex (Braak V/VI) 	Remote hemorrhage in the internal capsule of a contract of the internal capsule of a contract of the internal capsule of
7	56-60/F	PD	66-70	B STN	12	7	- 23 % (- 410 mg)	+ 219% (+ 46 J·s)	Head trauma	No	No	No	Yes	Not assessed	Intraparenchymal hemorrhages in the basal ganglia, thalamus, corru callosum, pons, and midbrain
8	56-60/M	PD	61-65	B STN	14	13 ^f	- 13% (- 200 mg)	- 2% (- 1 J·s)	Cardiac disease	Yes	No	No	Yes	 Diffuse beta-amyloid plaques in the middle frontal gyrus Rare neurofibrillary tangles in the hippocampus 	 Multifocal subacute infarcts in the middle frontal gyrus and cerebellum with foarm macrophages and glice is
9	51-55/M	Initial: PD Definitive: MSA – Parkinsonian type	51-55	B STN	8	62	- 56% (-1,086 mg)	- 31% (- 21 J·s)	Disease progresion	Yes	No	No	Yes	 Focal Purkinje cell loss and Bergmann gliosis in the cerebellum Glial cytoplasmic inclusions of alpha synuclein with rare neuronal inclusions in the middle frontal gyrus, cingulate gyrus, corpus callosum, hippocampus, amygdala, pons, substantia nigra, cerebellar white matter, dentate nucleus, and basal ganglia Rare neurofibrillary tangles in the hippocampus Scattered tau positive aggregates in the white matter, neocortex, amygdala, substantia nigra, pons, and cerebellum 	None .

3) months. ^d An additional lead (VIM) was implanted due to refractory right-sided tremor after the initial bilateral STN stimulation. ^e 198 months after implantation, the patient underwent left battery and extension removal due to neck infection. Left STN lead replacement, extension, and battery re-implantation was performed 3 months later. The total time accounts only for the time when DBS stimulation was active. ^f Entire DBS system removed due to right burr hole erosion and infection.

498

Abbreviations: B, bilateral; COPD, chronic obstructive pulmonary disease; DBS, deep brain stimulation; F, female; GPI, globus pallidus interna; LEDD, Levodopa equivalent
 daily dose; M, male; MSA, multiple system atrophy; n., number; NA, not available, STN, subthalamic nucleus; TEED, total electrical energy delivered; VIM, ventral intermediate
 nucleus.

502	Tab	Table 2. Characteristics of the postmortem neurohistopathological findings around the DBS electrode track for Parkinson's disease													
Author, year	DBS case n.	Age at DBS Sex	DBS targets	Electrode surface material	Clinical efficacy after DBS	Clinical decline after DBS	DBS duration in months	Cause of death	Gliosis at DBS site	Activated microglia at DBS lead	Neuronal loss at DBS l site	Other findings at DBS site	Nigra depigmentaion	Nig cell le	
Caparros-Lefebvre et al., 1994 ¹⁷	1	56-60 M	Vim	Pt/Ir	Yes	No	43	Stroke	Yes (1 mm perimeter)	NR	NR	Accumulation of lymphoid cells, macrophages, and giant cells (2 mm) around the electrode	Yes	Ye	
Haberler et al., 2000 ¹⁰	2	NR NR	L Vim	Pt/Ir	Yes	No	70	Myocardial infarction	Yes	No	No	-	Yes	Ye	
"	3	71-75 M	BL Vim	Pt/Ir	Yes	No	54	Cardiovascular failure	Yes	No	No	Mononuclear leukocytes	Yes	_Ye	
"	4	51-55 M	L Vim	Pt/Ir	Yes	No	45	Cardiovascular failure	Yes	No	No	Macrophages and reactive astrocytes	Yes	™ SYe	
"	5	56-60 M	BL Vim	Pt/Ir	Yes	No	45	Cardiovascular failure	Yes	NR	No	Multinucleated giant cells and reactive astrocytes	Yes	e Ye a	
"	6	41-45 M	R Vim	Pt/Ir	Yes	No	1	Astrocytoma	Yes	NR	No	Multinucleated giant cells	Yes	aliye	
"	7	76-80 M	BL Vim	Pt/Ir	Yes	No	15	Cardiovascular failure	Yes	Yes	No	More pronounced gliosis around lead track, multinucleated giant cells, and reactive astrocytes	Yes	ble unde	
"	8	66-70 F	BL STN	Pt/Ir	Yes	No	3	Drowning	Yes	Yes	No	More pronounced gliosis around lead track, multinucleated giant cells, and reactive astrocytes	Yes	a O Ye:	
"	9	61-65 M	L STN	Pt/Ir	Yes	No	2 days	Myocardial infarction	-	No	No	Fresh hemorrhage, perifocal edema, and numerous axonal spheroids	Yes	Ye:	
Henderson et al., 2001 ⁴²	10	66-70 M	L CM-Pf	Pt/Ir	Yes	Yes	48	Sepsis	Yes	NR	Yes	Extensive astrocytosis and small thalamotomy greater than the dimension of the electrode tip penetration	Yes	Ye:	
Berciano et al., 2002 ¹⁸	11*	61-65 M	BL STN	NR	Yes	No	21 days	Pulmonary embolus	NR	NR	NR	NR	Yes	Te:	
Henderson et al., 2002 ⁴³	12	51-55 M	BL STN	Pt/Ir	Yes	No	2	Aspiration pneumonia	Yes	Yes	Yes (mild)	TUNEL staining and analysis of cellular morphology did not show features of apoptosis, and astrocytosis	Yes	ernation.	
Counclis et al., 2003 ²⁹	13	61-65 M	BL STN	Pt/Ir	Yes	-	4 days	Pulmonary embolus	No	No	No	Fresh hemorrhage along tracks and minimal reactive changes	NR	₽ F Ye:	
Jarraya et al., 2003 ¹⁹	14	21-25 F	BL STN	NR	Yes	Yes	24	Pulmonary embolus	Yes	NR	NR	Large number of activated macrophages around the cavity and in the vicinity, and astrocytosis	Yes	. Ye	
Chou et al., 2004 ³⁰	15*	51-55 M	BL STN	NR	No	Yes	3	Aspiration pneumonia	Yes	NR	NR	Tracks associated with hemosiderin deposition, multinucleated giant cells, and neovascularization	Yes	Ye	
Henderson et al., 2004 ⁴⁴	16	61-65 M	L Vim	Pt/Ir	Yes	Yes	84	Ischemic heart disease	Yes	No	Yes	Hemosiderin deposition along the electrode track and astrocytosis	Yes	Ye	
Nielsen et al., 2007 ²⁰	17	71-75 M	BL STN	Pt/Ir	Yes	No	29	Accident	Yes (capsule)	NR	No	Lymphocytes, macrophages, neutrophilic granulocytes, occasional neurons in the capsule, and astrocytosis	Yes	Ye	
Guehl et al., 2008 ²¹	18	51-55 M	BL ZI	Pt/Ir	Yes	No	72	Dystonia (rhabdomyolysis)	Yes	NR	NR	None of the electrode contacts were located within the STN	NR	NR	

2	Table 2. Characteristics of the	postmortem neurohistop	athological findings ar	ound the DBS electrode	track for Parkinson's disease

Sun et al., 2008 ³¹	19	81-85 M	BL STN	Pt/Ir	Yes	No	71	Pnemonia	Yes	Yes	NR	Capsule with hemosiderin-laden macrophages, scattered lymphocytes, Rosenthal fibers, focal foreign-body giant cell reaction, and astrocytosis	Yes
Vedam-Mai et al., 2012 ³²	20	71-75 M	BL STN	NR	Yes	No	13	Cardiac arrest	Yes	No	No	Marked fibrosis around the cavity (right DBS lead tip), fibrocollagenous "capsule" confirmed by Mason's trichrome	Yes
Al-Helli et al., 2015 ⁶	21	66-70 M	BL STN	NR	NR	NR	72	NR	Yes	Yes	NR	Small collagenous scar with gliosis (Perl's stain positive) around track	Yes
De Vloo et al., 2018 ⁷	22	66-70 F	BL STN	Pt/Ir	Yes	No	144	Pneumonia	Yes	No	No	Minimal reactive astrocytosis, macrophages, fibrillary gliosis, and perivascular lymphocytic infiltration	Yes
Gelpi et al., 2021 ²²	23	61-65 M	BL STN	NR	Yes	No	51	Peritonitis	Yes	Yes	Yes	Astrogliosis	Yes
"	24	66-70 F	BL STN	NR	Yes	No	52	Pneumonia	Yes	Yes	Yes	Rosenthal fibers and astrogliosis	Yes
"	25	46-50 M	BL STN	NR	Yes	No	36	Pneumonia	Yes	Yes	Yes	Multinucleated giant cells, Rosenthal fibers, and astrogliosis	Yes
"	26	51-55 M	BL STN	NR	Yes	No	48	Cardiac arrest	Yes	Yes	Yes	Rosenthal fibers and astrogliosis	Yes

503 * DBS indicated for PD, but postmortem examination established diagnosis of multiple system atrophy

504 Abbreviations: BL, bilateral; CM-Pf, centromedian-parafasicular complex thalamic region; DBS, deep brain stimulation; F, female; L, left; M, male; n., number;

505 NR, not reported; Pt/Ir, platinum/iridium; R, right; STN, subthalamic nucleus; TUNEL, (TdT)-mediated UTP nick and labelling; Vim, ventralis intermedius

506 thalamic nucleus; ZI, zona incerta.

It is made available under a CC-BY-NC-ND 4.0 International license .

FIGURES AND FIGURE LEGENDS



Figure 1 (A-E). Macroscopic and microscopic tissue representations. (A) Coronal brain slice depicting gross bilateral tracts with close-up pop-out. Arrows denote tracts. (B) Hematoxylin & Eosin stain slide of midbrain with electrode tract in the nigra. Black scale = $200 \,\mu\text{m}$. (C) Lewy bodies in the nigra, arrow denotes Lewy body. White scale = $50 \,\mu\text{m}$. (D) Luxol fast blue stain on thalamus with electrode tract. Black scale = $200 \,\mu\text{m}$. (E) Glial fibrillary acidic protein statin on thalamus with tract. Black scale = $200 \,\mu\text{m}$.